Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022
SAN DIEGO, July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows:
- If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
- Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea.
- The Company's first FDA-approved product,Phexxi(lactic acid, citric acid and potassium bitartrate), is ahormone-free, on-demand prescription contraceptive vaginal gel.
- It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.